Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial
Seoul National University · Yonsei University · +6 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,067
total citations
- FWCI
- 39.02
- Percentile
- 100%
- References
- 24
Citations per year
Authors
17Topics & keywords
Topics
Keywords
- Capecitabine
- Medicine
- Oxaliplatin
- Clinical endpoint
- Internal medicine
- Interim analysis
- Population
- Gastrectomy
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.